Dupilumab in prurigo nodularis: 52-Week effectiveness and safety from the prospective multicenter BioDay registry
Open Access
- 18 July 2026
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (5) , 1505-1508
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
This publication has 5 references indexed in Scilit:
- Dupilumab in moderate‐to‐severe prurigo nodularis: Real‐world data from early access programJournal of the European Academy of Dermatology and Venereology, 2026
- Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical TrialsAmerican Journal of Clinical Dermatology, 2025
- The SWITCH algorithm: An expert consensus on treat‐to‐target criteria for chronic prurigoJournal of the European Academy of Dermatology and Venereology, 2025
- Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)JAAD International, 2024
- Long‐term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real‐world retrospective studyJournal of the European Academy of Dermatology and Venereology, 2024